Dark
Streaming/Mobile
OldĀ Site
Home
Products
Help
Contact Us
Your Account
System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
18:36:00 EST Tue 17 Nov 2026
Quotes
Streaming/Mobile
Quick Quotes (x20)
Symbol Search
Company Search
Market Depth
US Options
Montreal Options
Foreign Exchange
Download Close Prices
Short History
Quotes Help
Charts
12 Month Chart
Advanced Chart
Live Intraday Chart
Live Historical Chart
Live Java Intraday Chart
Live Java Historical Chart
Charts Help
News
News Search
SEDAR+ Search
SEDAR+ Alerts
News Help
Indexes
Major Indexes
US incl Dow Jones
NASDAQ
S&P CME
PBOT - Phil Ex
TSX - Toronto
TSX-V - TSX Venture
Indexes Help
Portfolio
View Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Value Portfolio
All Portfolios
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Edit Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Chart Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Live Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
View Portfolio News
Daily Summary
Portfolio Help
Analytics
Exchange Statistics
Most Active
Live Most Active
Block Trades
Broker Trades
Halted Stocks
Dividends
Participants
Companies
Trade Workstation
Company Picker
Short Positions
Broker Codes
Analytics Help
Mutual Funds
Mutual Fund Search
Targeted Holder Search
SEDAR+ Fund Search
Mutual Fund Help
Enter Symbol
or Name
USA
CA
Quote
Chart
News
Closes
Depth
Forgot password?
Trouble logging in?
Login ID:
Password:
Save
Q:OTLK
- OUTLOOK THERAPEUTICS INC -
https://outlooktherapeutics.com
18:36:00 EST
Sym-X
Bid - Ask
Last
Chg
%Ch
Vol
$Vol
#Tr
Open-Hi-Lo
Year Hi-Lo
Last Tr
News
Delay
OTLK
- Q
1.4
0.35
·
0.3896
1.0
0.3606
-0.0354
-8.9
5,271.8
1,620
5,745
0.3875
0.3913
0.35
2.5375 0.1611
18:15:45
Oct 09
15 min
RT 2¢
Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
Nasdaq Indicators -- Market:
Nasdaq
-- Bid Tick:
Down
-- UPC Restricted:
No
Financial Status:
Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
Fundamentals
·
Holders
·
Trade Workstation
·
Market Depth
·
3 Month Closes
·
Technical Charts
1 yr
|
2 yr
|
3 yr
|
5 yr
|
10 yr
|
15 yr
|
20 yr
·
Live Charts
1 yr
|
1 day
·
1yr Bulletins
·
Historical
·
Portfolio
Recent Trades - Last 10 of 5745
More trades...
Time ET
Ex
Price
Change
Volume
18:15:45
Q
0.375
-0.021
250
18:14:49
Q
0.37
-0.026
604
18:13:35
Q
0.362
-0.034
150
18:13:22
Q
0.3626
-0.0334
4,137
18:13:06
Q
0.37
-0.026
300
18:02:34
Q
0.3742
-0.0218
1,000
17:35:55
Q
0.3749
-0.0211
300
17:18:06
Q
0.37
-0.026
1,000
17:12:00
Q
0.375
-0.021
28
17:10:09
Q
0.375
-0.021
1,000
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
Recent Bulletins
News Releases
In The News
Other
Date ET
Symbol
Type
Headline
2026-10-09 08:30
U:OTLK
News Release
200
Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
2026-10-06 09:20
U:OTLK
News Release
200
Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company's Next Chapter in Virtual Investor Discussion
2026-10-01 09:01
U:OTLK
News Release
200
Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA(TM) (bevacizumab-vikg)
2026-09-11 07:00
U:OTLK
News Release
200
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
2026-09-10 09:10
U:OTLK
News Release
200
Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA(TM) in Virtual Investor CEO Connect Segment
2026-08-27 16:05
U:OTLK
News Release
200
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA(TM)
2026-08-27 09:01
U:OTLK
News Release
200
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor "Why Now" On-Demand Conference
2026-08-14 07:15
U:OTLK
News Release
200
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA(TM)
2026-08-12 21:45
U:OTLK
News Release
200
Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
2026-08-12 16:01
U:OTLK
News Release
200
Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
2026-08-06 08:45
U:OTLK
News Release
200
Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026
2026-07-24 14:40
U:OTLK
News Release
200
Outlook Therapeutics Announces LYTENAVA(TM) FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD
2026-06-16 08:02
U:OTLK
News Release
200
Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA(TM) (bevacizumab-vikg) as a Treatment for Wet AMD
2026-06-01 08:46
U:OTLK
News Release
200
Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA(TM) (bevacizumab-vikg)
2026-05-28 16:00
U:OTLK
News Release
200
Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2026-05-26 07:00
U:OTLK
News Release
200
Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA(TM) (bevacizumab-vikg)
2026-05-15 16:05
U:OTLK
News Release
200
Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
2026-04-23 16:05
U:OTLK
News Release
200
Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
2026-04-22 08:30
U:OTLK
News Release
200
Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2026-04-21 09:05
U:OTLK
News Release
200
Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA(TM) (bevacizumab-vikg)